03:46 PM EST - Immunovaccine Inc. : Announced that the first patient with recurrent ovarian cancer has been treated in a Phase 1b clinical study of Immunovaccine's novel T cell activating therapy, DPX-Survivac, in combination with epacadostat and low-dose cyclophosphamide. Immunovaccine Inc.
shares T.IMV are trading up $0.01 at $0.79.
